These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12852825)

  • 41. Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors.
    Dussault I; Forman BM
    Prostaglandins Other Lipid Mediat; 2000 Jun; 62(1):1-13. PubMed ID: 10936411
    [No Abstract]   [Full Text] [Related]  

  • 42. [Control of cellular differentiation by PPARs].
    Grimaldi PA
    Journ Annu Diabetol Hotel Dieu; 2001; ():11-21. PubMed ID: 11565452
    [No Abstract]   [Full Text] [Related]  

  • 43. The pleiotropic nature of the vascular PPAR gene regulatory pathway.
    Kelly DP
    Circ Res; 2001 Nov; 89(11):935-7. PubMed ID: 11717147
    [No Abstract]   [Full Text] [Related]  

  • 44. Receptors and mechanisms of action of prostacyclin in preserving non-mucosal cell integrity.
    Nicosia S; Oliva D; Paoletti R
    Gastroenterol Clin Biol; 1985; 9(12 Pt 2):33-6. PubMed ID: 2422088
    [No Abstract]   [Full Text] [Related]  

  • 45. Prostacyclin receptors: Transcriptional regulation and novel signalling mechanisms.
    Reid HM; Kinsella BT
    Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt A):70-82. PubMed ID: 25936507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Focus issue: the signaling skinny on obesity.
    Chong LD; Adler EM; Ray LB
    Sci STKE; 2003 Feb; 2003(169):EG2. PubMed ID: 12582198
    [No Abstract]   [Full Text] [Related]  

  • 47. Overview. PPAR and cardiovascular risk.
    Fruchart JC
    J Cardiovasc Risk; 2001 Aug; 8(4):185-6. PubMed ID: 11550995
    [No Abstract]   [Full Text] [Related]  

  • 48. [PPARs and signal transduction of prostaglandins].
    Hatae T; Tanabe T
    Seikagaku; 2002 Jul; 74(7):551-4. PubMed ID: 12187788
    [No Abstract]   [Full Text] [Related]  

  • 49. Receptor-mediated toxicity.
    Gustafsson JA
    Toxicol Lett; 1995 Dec; 82-83():465-70. PubMed ID: 8597095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cell signalling and cancer].
    Robert J
    Bull Cancer; 2010 Nov; 97(11):1215-22. PubMed ID: 21047720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The human prostacyclin receptor from structure function to disease.
    Martin KA; Gleim S; Elderon L; Fetalvero K; Hwa J
    Prog Mol Biol Transl Sci; 2009; 89():133-66. PubMed ID: 20374736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostacyclin as a Potential Novel Means to Manipulate Type 2 Innate Lymphoid Cell Function.
    Saglani S; Lloyd CM
    Am J Respir Crit Care Med; 2016 Jan; 193(1):2-4. PubMed ID: 26720782
    [No Abstract]   [Full Text] [Related]  

  • 53. Piperidine derivatives as nonprostanoid IP receptor agonists.
    Hayashi R; Sakagami H; Koiwa M; Ito H; Miyamoto M; Isogaya M
    Bioorg Med Chem Lett; 2016 May; 26(9):2360-4. PubMed ID: 26996371
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Yap"-ing about the Antifibrotic Benefits of Prostacyclin.
    Huang SK
    Am J Respir Cell Mol Biol; 2019 May; 60(5):499-500. PubMed ID: 30562049
    [No Abstract]   [Full Text] [Related]  

  • 55. Prostacyclin receptors of a neuronal hybrid cell line. Divalent citations and ligand-receptor coupling.
    MacDermot J; Blair IA; Cresp TM
    Biochem Pharmacol; 1981 Aug; 30(15):2041-4. PubMed ID: 6271132
    [No Abstract]   [Full Text] [Related]  

  • 56. Comment on: "pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag".
    Srinivas NR
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):371-2. PubMed ID: 26293236
    [No Abstract]   [Full Text] [Related]  

  • 57. Targeting prostacyclin: all gain with no pain?
    Rondina MT
    Blood; 2023 Nov; 142(18):1506-1507. PubMed ID: 37917084
    [No Abstract]   [Full Text] [Related]  

  • 58. Authors' reply to Srinivas: "pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag".
    Kaufmann P; Dingemanse J
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):373-4. PubMed ID: 26293237
    [No Abstract]   [Full Text] [Related]  

  • 59. Increasing the complexity of coactivation in nuclear receptor signaling.
    Freedman LP
    Cell; 1999 Apr; 97(1):5-8. PubMed ID: 10199396
    [No Abstract]   [Full Text] [Related]  

  • 60. Special issue on non-genomic actions of nuclear receptors: An evolutionary and physiological perspective.
    Arnal JF; Fontaine C; Adlanmerini M; Lenfant F
    Mol Cell Endocrinol; 2023 Mar; 564():111884. PubMed ID: 36739891
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.